Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)

Matthew C Foster, MD, Philip A. Roehrs, MD, George E Hucks, MD, Natalie S Grover, MD, Paul M. Armistead, MD PhD, Katarzyna Jamieson, MD, Faith Brianne Buchanan, PA, J. Kaitlin C Morrison, PhD, Spencer Laing, BA, Catherine Joyce Arago Cheng, BS, Jonathan S. Serody, MD, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139051

Published: 2020

Journal Articles

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Nicholas P. Tschernia, MD, Vaibhav Kumar, MBBS,MS, Dominic T. Moore, MPH, MS, Benjamin G. Vincent, MD, Callie C. Coombs, MD, Hendrik Van Deventer, MD, Matthew C. Foster, MD, Amy E. DeZern, MD, Leo Luznik, MD, Marcie L. Riches, MDMS, Jonathan S. Serody, MD, Ivana Gojo, MD, Joshua F. Zeidner, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-138786

Published: 2020

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Epigenetic Plasticity of Type II Innate Lymphoid Cells in the Lower Gastrointestinal Tract

Sonia J. Laurie, PhD BSc, Danny W. Bruce, PhD, Hemamalini Bommiasamy, PhD, Melodie P Noel, BS, Joseph P. Foster, III, PhD, Ian J. Davis, MD PhD, Samantha G. Pattenden, PhD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 1921.

https://doi.org/10.1182/blood-2019-126823

Published: 2019

Journal Articles

Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD

Danny W. Bruce, PhD, Oleg Kolupaev, PhD, Hemamalini Bommiasamy, PhD, Heather Stefanski, MD PhD, Bruce R. Blazar, MD, James M. Coghill, Jr., MD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 3205.

https://doi.org/10.1182/blood-2019-126848

Published: 2019

Journal Articles

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Timothy J Voorhees, MD, Natalie S Grover, MD, Anne Beaven, MD, Steven I Park, MD, J. Kaitlin Morrison, PhD, Catherine Joyce Arago Cheng, BS, Spencer Laing, BA, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 3233.

https://doi.org/10.1182/blood-2019-122846

Published: 2019

Journal Articles

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Blood (2018) 132 (Supplement 1): 4054.

https://doi.org/10.1182/blood-2018-99-116608

Published: 2018

Journal Articles

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

Blood (2018) 132 (Supplement 1): 681.

https://doi.org/10.1182/blood-2018-99-113534

Published: 2018

Journal Articles

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Anastasia Ivanova, PhD, Matthew Foster, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik Van Deventer, MD, Richard Scibilia, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Katherine Pepin, Lori Vaught, Nancy Vogler, Ivana Gojo, MD, Leo Luznik, MD, Jonathan S Serody, MD

Blood (2017) 130 (Supplement 1): 1349.

https://doi.org/10.1182/blood.V130.Suppl_1.1349.1349

Published: 2017

Journal Articles

Bim Regulates the Survival and Suppressive Capability of CD8+ Foxp3+ Regulatory T Cells during Graft Versus Host Disease

Benjamin G. Vincent, MD, Kimberle A. Agle, PhD, Ludovic Belle, PhD, Vivan Zhou, PhD, Clint Piper, BS, Warren D Shlomchik, MD, Jonathan S Serody, MD, William R. Drobyski, MD

Blood (2017) 130 (Supplement 1): 209.

https://doi.org/10.1182/blood.V130.Suppl_1.209.209

Published: 2017

Journal Articles

A Critical Role for Donor-Derived IL-22 in Cutaneous Chronic Gvhd

Blood (2017) 130 (Supplement 1): 69.

https://doi.org/10.1182/blood.V130.Suppl_1.69.69

Published: 2017

Journal Articles

A Novel Process for the Expansion of Functional Human ILC2 Cells for GCHD Prevention

Yan Xing, MDPhD, Heather Stefanski, MD PhD, Danny W. Bruce, PhD, Keli Lee Hippen, PhD, James M. Coghill, Jr., MD, Karen McKinnon, PhD, Shannon Reisdorf, BS, Bruce Blazar, MD, Jonathan S Serody, MD

Blood (2017) 130 (Supplement 1): 4432.

https://doi.org/10.1182/blood.V130.Suppl_1.4432.4432

Published: 2017

Journal Articles

Mechanism and Activity of ILC2 Cells Post Allo-BMT

Danny W Bruce, PhD, Heather E Stefanski, MD PhD, Benjamin G. Vincent, MD, Trisha Dant, BS, Shannon Reisdorf, BS, Hemamalini Bommiasamy, PhD, David Serody, Justin E Wilson, PhD, Karen McKinnon, PhD, Warren D Shlomchik, MD, Paul M. Armistead, MD PhD, Jenny PY Ting, PhD, John T Woosley, MD PhD, Dietmar MW Zaiss, PhD, Bruce R. Blazar, MD, Andrew NJ McKenzie, PhD, James Coghill, MD, Jonathan S. Serody, MD

Blood (2016) 128 (22): 1155.

https://doi.org/10.1182/blood.V128.22.1155.1155

Published: 2016

Journal Articles

Pirfenidone Reverses Murine Chronic Graft Versus Host Disease

Jing Du, Ryan P Flynn, PhD, Katelyn Paz, Ante Vulic, MD, Tara M. Robinson, MD PhD, Katie E Lineburg, BSc, Kelli P A Macdonald, PhD, Geoffrey R Hill, Jonathan S Serody, MD, Ivan Maillard, MD PhD, Angela Panoskaltsis-Mortari, PhD, Timothy Schacker, MD, Leo Luznik, MD, Bruce R. Blazar, MD

Blood (2016) 128 (22): 1158.

https://doi.org/10.1182/blood.V128.22.1158.1158

Published: 2016

Journal Articles

Absence of Coronin 1B in Donor T Cells Diminishes Acute Gvhd By Impairing T Cell Accumulation in Secondary Lymphoid Tissue

Trisha Dant, BS, Danny Bruce, PhD, Leshara Fulton, PhD, Michelle West, BS, Niko Foger, PhD, Jonathan S. Serody, MD

Blood (2015) 126 (23): 1880.

https://doi.org/10.1182/blood.V126.23.1880.1880

Published: 2015

Journal Articles

Chronic GvHD Is Characterized By Impaired B Cell Development in the Bone Marrow

Oleg Kolupaev, PhD, Michelle West, BS, Bruce R. Blazar, MD, Stephen Tilley, MD, James Coghill, MD, Jonathan S. Serody, MD

Blood (2015) 126 (23): 1883.

https://doi.org/10.1182/blood.V126.23.1883.1883

Published: 2015

Journal Articles

Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality

Blood (2015) 126 (23): 147.

https://doi.org/10.1182/blood.V126.23.147.147

Published: 2015

Journal Articles

Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease

Bruce R. Blazar, MD, Roddy S. O'Connor, PhD, Michael C. Milone, MD PhD, Michael L. Dustin, PhD, James L. Riley, PhD, Benjamin G. Vincent, MD, Jonathan S. Serody, MD, Ryan P Flynn, PhD, Katelyn Paz, Jing Du, Angela Panoskaltsis-Mortari, PhD, Miller Jeffrey, MD, Rafi Ahmed, PhD, Laurence A. A. Turka, MD, Gordon J. Freeman, PhD, Arlene H. Sharpe, MDPhD, Asim Saha, PhD

Blood (2015) 126 (23): SCI-8.

https://doi.org/10.1182/blood.V126.23.SCI-8.SCI-8

Published: 2015

Journal Articles

Protein Kinase C-Theta Interacts with mTORC2 and Vimentin to Limit Regulatory T-Cell Function

Cameron McDonald-Hyman, BA, Govindarajan Thangavelu, PhD, James Muller, Guoan Zhang, PhD, Sudha Kumari, PhD, Asim Saha, PhD, Brent H. Koehn, PhD, Jason S. Mitchell, PhD, Brian T Fife, PhD, Jonathan S. Serody, MD, Mark J. Osborn, PhD, Keli L. Hippen, PhD, Ameeta Kelekar, PhD, David H. Munn, MD, Amnon Altman, PhD, Thomas A. Neubert, PhD, Michael L. Dustin, PhD, Bruce R. Blazar, MD

Blood (2015) 126 (23): 849.

https://doi.org/10.1182/blood.V126.23.849.849

Published: 2015

NARROW

Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Epigenetic Plasticity of Type II Innate Lymphoid Cells in the Lower Gastrointestinal Tract

Third Party Type 2 Innate Lymphoid Cells Treat and Prevent GI Tract Acute GvHD

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Bim Regulates the Survival and Suppressive Capability of CD8+ Foxp3+ Regulatory T Cells during Graft Versus Host Disease

A Critical Role for Donor-Derived IL-22 in Cutaneous Chronic Gvhd

A Novel Process for the Expansion of Functional Human ILC2 Cells for GCHD Prevention

Mechanism and Activity of ILC2 Cells Post Allo-BMT

Pirfenidone Reverses Murine Chronic Graft Versus Host Disease

Absence of Coronin 1B in Donor T Cells Diminishes Acute Gvhd By Impairing T Cell Accumulation in Secondary Lymphoid Tissue

Chronic GvHD Is Characterized By Impaired B Cell Development in the Bone Marrow

Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality

Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease

Protein Kinase C-Theta Interacts with mTORC2 and Vimentin to Limit Regulatory T-Cell Function

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only